Evidence map›Paper›PMID 34645858›Full record

ArticleScientific reports2021

Viability fingerprint of glioblastoma cell lines: roles of mitotic, proliferative, and epigenetic targets.

Darja Lavogina, Tõnis Laasfeld, Markus Vardja, Helen Lust, Jana Jaal

Abstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Darja LavoginaInstitute of Clinical Medicine, University of Tartu, L. Puusepa 8, 50406, Tartu, Estonia. darja.lavogina@ut.ee.
Tõnis LaasfeldInstitute of Chemistry, University of Tartu, Tartu, Estonia.
Markus VardjaDepartment of Radiotherapy and Oncological Therapy, Tartu University Hospital, Tartu, Estonia.
Helen LustInstitute of Clinical Medicine, University of Tartu, L. Puusepa 8, 50406, Tartu, Estonia.
Jana JaalInstitute of Clinical Medicine, University of Tartu, L. Puusepa 8, 50406, Tartu, Estonia. jana.jaal@kliinikum.ee.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the use of multimodal treatment combinations, the prognosis of glioblastoma (GB) is still poor. To prevent rapid tumor recurrence, targeted strategies for the treatment of GB are widely sought. Here, we compared the efficacy of focused modulation of a set of signaling pathways in two GB cell lines, U-251 MG and T98-G, using a panel of thirteen compounds targeting cell cycle progression, proliferation, epigenetic modifications, and DNA repair mechanism. In parallel, we tested combinations of these compounds with temozolomide and lomustine, the standard chemotherapy agents used in GB treatment. Two major trends were found: within individual compounds, the lowest IC

Indexed as

Brain NeoplasmsGlioblastomaAntineoplastic Combined Chemotherapy ProtocolsAzacitidineCell CycleCell Line, TumorEpigenesis, GeneticGene Expression Regulation, NeoplasticHumansLomustineTemozolomideAzacitidineLomustineTemozolomide

Identifiers

PMID34645858
PMCPMC8514540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.